日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Escherichia fergusonii Glycine dehydrogenase [decarboxylating] (gcvP), partial CSB-YP009493EOR
CSB-EP009493EOR
CSB-BP009493EOR
CSB-MP009493EOR
CSB-EP009493EOR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia fergusonii Peptide deformylase (def) CSB-YP017707EOR
CSB-EP017707EOR
CSB-BP017707EOR
CSB-MP017707EOR
CSB-EP017707EOR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia fergusonii 6-phosphofructokinase (pfkA) CSB-YP017822EOR
CSB-EP017822EOR
CSB-BP017822EOR
CSB-MP017822EOR
CSB-EP017822EOR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Glycine dehydrogenase [decarboxylating] (gcvP), partial CSB-YP009493EOO
CSB-EP009493EOO
CSB-BP009493EOO
CSB-MP009493EOO
CSB-EP009493EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Translation initiation factor IF-2 (infB), partial CSB-YP015164EOO
CSB-EP015164EOO
CSB-BP015164EOO
CSB-MP015164EOO
CSB-EP015164EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Queuine tRNA-ribosyltransferase (tgt) CSB-YP019146EOO
CSB-EP019146EOO
CSB-BP019146EOO
CSB-MP019146EOO
CSB-EP019146EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 ATP synthase subunit beta (atpD) CSB-YP002350EOO
CSB-EP002350EOO
CSB-BP002350EOO
CSB-MP002350EOO
CSB-EP002350EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O8 Serine hydroxymethyltransferase (glyA) CSB-YP021274EOO
CSB-EP021274EOO
CSB-BP021274EOO
CSB-MP021274EOO
CSB-EP021274EOO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 Queuine tRNA-ribosyltransferase (tgt) CSB-YP019146EOK
CSB-EP019146EOK
CSB-BP019146EOK
CSB-MP019146EOK
CSB-EP019146EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 ATP synthase subunit beta (atpD) CSB-YP002350EOK
CSB-EP002350EOK
CSB-BP002350EOK
CSB-MP002350EOK
CSB-EP002350EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 3-ketoacyl-CoA thiolase (fadI) CSB-YP001117EOK
CSB-EP001117EOK
CSB-BP001117EOK
CSB-MP001117EOK
CSB-EP001117EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 Nicotinate phosphoribosyltransferase (pncB) CSB-YP015451EOK
CSB-EP015451EOK
CSB-BP015451EOK
CSB-MP015451EOK
CSB-EP015451EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 Triosephosphate isomerase (tpiA) CSB-YP024102EOK
CSB-EP024102EOK
CSB-BP024102EOK
CSB-MP024102EOK
CSB-EP024102EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 Peptide chain release factor 1 (prfA) CSB-YP015197EOK
CSB-EP015197EOK
CSB-BP015197EOK
CSB-MP015197EOK
CSB-EP015197EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 tRNA dimethylallyltransferase (miaA) CSB-YP024529EOK
CSB-EP024529EOK
CSB-BP024529EOK
CSB-MP024529EOK
CSB-EP024529EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O45:K1 NAD-dependent malic enzyme (maeA) CSB-YP013633EOK
CSB-EP013633EOK
CSB-BP013633EOK
CSB-MP013633EOK
CSB-EP013633EOK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O81 Phosphatidylserine decarboxylase proenzyme (psd) CSB-YP018033EOP
CSB-EP018033EOP
CSB-BP018033EOP
CSB-MP018033EOP
CSB-EP018033EOP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O81 NAD-dependent malic enzyme (maeA) CSB-YP013633EOP
CSB-EP013633EOP
CSB-BP013633EOP
CSB-MP013633EOP
CSB-EP013633EOP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O17:K52:H18 Nicotinate phosphoribosyltransferase (pncB) CSB-YP015451EOG
CSB-EP015451EOG
CSB-BP015451EOG
CSB-MP015451EOG
CSB-EP015451EOG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O17:K52:H18 Cardiolipin synthase (cls), partial CSB-YP005985EOG1
CSB-EP005985EOG1
CSB-BP005985EOG1
CSB-MP005985EOG1
CSB-EP005985EOG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×